User login
Key clinical point: Adjuvant chemotherapy (ACT) after neoadjuvant chemotherapy (NACT) and surgery significantly improved survival in patients with locally advanced gastric cancer (LAGC) with a lymph node ratio (LNR) of ≥9%.
Major finding: At 3 years, the overall survival (OS) was significantly higher in patients who received ACT (60.1% vs. 49.3%; P = .02) vs. those who did not. ACT was associated with significantly improved OS at 3 years in patients with higher (≥9%) LNR (46.6% vs. 21.7%; P < .001). ACT improved OS at 3 years in patients with an LNR of ≥9% in an external validation cohort (53.0% vs. 26.3%; P = .04).
Study details: This article reports on a multicenter retrospective cohort study including 353 patients with LAGC undergoing curative-intent gastrectomy after NACT and an external validation cohort of 109 patients.
Disclosures: No funding source was identified for this study. The authors declared no conflicts of interest.
Source: Lin J-X et al. Association of adjuvant chemotherapy with overall survival among patients with locally advanced gastric cancer after neoadjuvant chemotherapy. JAMA Netw Open. 2022;5(4):e225557 (Apr 1). Doi: 10.1001/jamanetworkopen.2022.5557
Key clinical point: Adjuvant chemotherapy (ACT) after neoadjuvant chemotherapy (NACT) and surgery significantly improved survival in patients with locally advanced gastric cancer (LAGC) with a lymph node ratio (LNR) of ≥9%.
Major finding: At 3 years, the overall survival (OS) was significantly higher in patients who received ACT (60.1% vs. 49.3%; P = .02) vs. those who did not. ACT was associated with significantly improved OS at 3 years in patients with higher (≥9%) LNR (46.6% vs. 21.7%; P < .001). ACT improved OS at 3 years in patients with an LNR of ≥9% in an external validation cohort (53.0% vs. 26.3%; P = .04).
Study details: This article reports on a multicenter retrospective cohort study including 353 patients with LAGC undergoing curative-intent gastrectomy after NACT and an external validation cohort of 109 patients.
Disclosures: No funding source was identified for this study. The authors declared no conflicts of interest.
Source: Lin J-X et al. Association of adjuvant chemotherapy with overall survival among patients with locally advanced gastric cancer after neoadjuvant chemotherapy. JAMA Netw Open. 2022;5(4):e225557 (Apr 1). Doi: 10.1001/jamanetworkopen.2022.5557
Key clinical point: Adjuvant chemotherapy (ACT) after neoadjuvant chemotherapy (NACT) and surgery significantly improved survival in patients with locally advanced gastric cancer (LAGC) with a lymph node ratio (LNR) of ≥9%.
Major finding: At 3 years, the overall survival (OS) was significantly higher in patients who received ACT (60.1% vs. 49.3%; P = .02) vs. those who did not. ACT was associated with significantly improved OS at 3 years in patients with higher (≥9%) LNR (46.6% vs. 21.7%; P < .001). ACT improved OS at 3 years in patients with an LNR of ≥9% in an external validation cohort (53.0% vs. 26.3%; P = .04).
Study details: This article reports on a multicenter retrospective cohort study including 353 patients with LAGC undergoing curative-intent gastrectomy after NACT and an external validation cohort of 109 patients.
Disclosures: No funding source was identified for this study. The authors declared no conflicts of interest.
Source: Lin J-X et al. Association of adjuvant chemotherapy with overall survival among patients with locally advanced gastric cancer after neoadjuvant chemotherapy. JAMA Netw Open. 2022;5(4):e225557 (Apr 1). Doi: 10.1001/jamanetworkopen.2022.5557